GlassScriptPhysician profile
Lynn S Crawford
NPI 1134280274
$6,077.63
in general payments reported to CMS, 2019-2025
24 companies · $746 in 2025
The $746 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $426 · 2021: $784 · 2022: $1,485 · 2023: $709 · 2024: $965 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,007.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $986.75 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $738.11 | 2019-2024 | |
| Abbvie INC. | $655.44 | 2021-2025 | |
| Inari Medical, INC. | $502.48 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $462.06 | 2021-2025 | Veklury |
| Alexion Pharmaceuticals, INC. | $414.74 | 2022-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $354.72 | 2020-2025 | Eliquis |
| Abbott Laboratories | $255.03 | 2019-2022 | |
| Boston Scientific Corporation | $172.36 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $162.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $84.42 | 2019-2020 | |
| Biomerieux INC | $48.38 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.86 | 2024 | Lifevest |
| Allergan, INC. | $34.32 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $32.55 | 2022 | |
| Novo Nordisk INC | $21.09 | 2024 | Ozempic, Rybelsus |
| Genzyme Corporation | $18.25 | 2020 | |
| Melinta Therapeutics, LLC | $16.32 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Astellas Pharma US INC | $16.15 | 2019 | |
| Breas Medical, INC. | $15.21 | 2025 | Vivo 45 Ls |
| Merz North America, INC. | $14.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2023 | Xifaxan |
| Cvrx, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.